Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply

Affiliations

¹ Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
² University Hospital Gasthuisberg, Leuven, Belgium.
³ Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
⁴ Formerly of Takeda Development Centre Europe Ltd, London, UK.
⁵ Takeda Development Centre Europe Ltd, London, UK.
⁶ Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Comment

U Mahadevan et al. Aliment Pharmacol Ther. 2018 Aug.

. 2018 Aug;48(3):388-389.

doi: 10.1111/apt.14855.

¹ Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
² University Hospital Gasthuisberg, Leuven, Belgium.
³ Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
⁴ Formerly of Takeda Development Centre Europe Ltd, London, UK.
⁵ Takeda Development Centre Europe Ltd, London, UK.
⁶ Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

No abstract available

Comment on

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Mahadevan U, et al. Aliment Pharmacol Ther. 2017 Apr;45(7):941-950. doi: 10.1111/apt.13960. Epub 2017 Feb 7. Aliment Pharmacol Ther. 2017. PMID: 28169436
Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.
Julsgaard M, Kjeldsen J, Brock B, Baumgart DC. Julsgaard M, et al. Aliment Pharmacol Ther. 2018 Aug;48(3):386-388. doi: 10.1111/apt.14837. Aliment Pharmacol Ther. 2018. PMID: 29998502 No abstract available.